Bicyclomycin, a new antibiotic. 3. In vitro and in vivo antimicrobial activity.
D000818:Animals; D000900:Anti-Bacterial Agents / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D001419:Bacteria / Q000187:drug effects; D001798:Blood Proteins / Q000378:metabolism; D001952:Bridged-Ring Compounds / Q000494:pharmacology; D004352:Drug Resistance, Microbial; D004355:Drug Stability; D004755:Enterobacteriaceae / Q000187:drug effects; D004926:Escherichia coli / Q000187:drug effects; D004927:Escherichia coli Infections / Q000188:drug therapy; D006801:Humans; D007709:Klebsiella / Q000187:drug effects; D008297:Male; D051379:Mice; D008826:Microbial Sensitivity Tests; D009268:Nalidixic Acid / Q000494:pharmacology; D011485:Protein Binding; D051381:Rats; D012475:Salmonella / Q000187:drug effects; D012760:Shigella / Q000187:drug effects
D000900:Anti-Bacterial Agents; D001798:Blood Proteins; D001952:Bridged-Ring Compounds; D009268:Nalidixic Acid